User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

10991

Interactions with Platform & by Email *

INTERACTIONS

1319

Unique # Participated *

PARTICIPANTS

330

Responses Validated *

VALIDATIONS

36

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Market Highlights.....II-1
Current and Future Analysis.....II-1
1$100
   Industry Dynamics and Changing Scenario.....II-2
Intense Competition in the Antidepressants Marketplace.....II-2
1$100
   Global Antidepressants Market (2004): Major Products in the Pipeline.....II-3 1$100
   Table 1: Leading Brands in the Global Antidepressants Market (2001 & 2002): Sales in US$ Million for Seroxat/Paxil, Zoloft, Effexor, Cipramil/ Celexa, Wellbutrin, Prozac, Remeron, Fluoxetine Par, Serzone, and Fluoxetine Barr (include corresponding Graphs/Chart) .....II-41$300
   Table 2: Leading Drugs in the Global Antidepressants Market (2003): Sales in US$ Million for Seroxat, Zoloft, Effexor, Cipramil/ Celexa, Wellbutrin, Cipralex/ Lexapro, Prozac, and Remeron (include corresponding Graphs/Chart) .....II-51$300
   SSRI/SNRI Brands in the Global Antidepressants Market (2002-2006): Sales in US$
  Million by Geographic Region for Cipralex/Lexapro, Effexor, Cipramil/ Celexa,
    Paxil, Zoloft, and Cymbalta.....II-6
1$100
   SSRIs Garnering Major Share of the Market.....II-7
Table 3: Leading Brands in the Global SSRI Antidepressants Market (2003): Percentage Breakdown of Value Sales for Zoloft, Paxil and Paxil CR, Generic Fluoxetine, Celexa, Lexapro, Prozac, Prozac Weekly, and Others (include corresponding Graphs/Chart) .....II-7
1$300
   Emerging Antidepressant Classes Pose Threat to SSRI.....II-8
Market Snapshots.....II-8
1$100
   New Drugs Making Way into the Market.....II-9
Prozac Patent Expiry Opens Door for Generic Versions.....II-9
Generic Antidepressants to Hit Market Soon.....II-9
1$100
   TCA Antidepressants Still in Use.....II-10
Improved Marketing Spurs Growth.....II-10
Westerners Fight Depression Blues; Americans Top the List.....II-10
Antidepressants High in Demand but Fail to Satisfy Consumers.....II-10
1$100
   No One is Immune: Not Even Animals!.....II-11
Patent Expiry Disturbs Antidepressants Producers.....II-11
Unlicensed Antidepressants Pose Danger to Youth Safety.....II-11
1$100
   Global Antidepressants Market (2003): Regulations Governing Select Antidepressants
  Use in Children.....II-12
Growing Safety Concerns – Antidepressants Under Fire.....II-12
The Debate Flares.....II-12
Are Antidepressants Totally Safe? A Moot but Important Question.....II-12
1$100
   Manufacturers Vociferous in their Protests.....II-13
No Satisfactory Answers Yet – The Wait Grows Longer.....II-13
Global Antidepressants Market: Drug Regulation for Kids in Britain and the United
  States.....II-13
1$100
   What is depression?.....II-14
Symptoms of Depression.....II-14
Causes of Depression.....II-14
1$100
   Types of Depression and Related Disorders.....II-15
Major Depressive Disorders (Major Depression).....II-15
Dysthymic Disorder (Minor Depression).....II-15
Bipolar Disorder.....II-15
Related Disorder Types.....II-15
1$100
   Seasonal Affective Disorder.....II-16
Premenstrual Dysphoric Disorder (PMDD).....II-16
Anxiety Disorders.....II-16
Obsessive Compulsive Disorder.....II-16
Generalized Anxiety Disorder.....II-16
Panic Disorder.....II-16
Treatment of Depression.....II-16
1$100
   Options Available in Depression Treatment.....II-17
Psychotherapy or Psychiatric Consultation.....II-17
Pharmacotherapy.....II-17
Combination of Psychotherapy and Pharmacotherapy.....II-17
Herbal and Nutritional Treatment.....II-17
Exercise.....II-17
How Can Depression Treatment become More Effective?.....II-17
1$100
   Global Antidepressants Market: Favorable Drugs Under Specific Conditions.....II-18
Global Antidepressants Market: Unfavorable Drugs Under Specific Conditions.....II-18
1$100
   Treatment-Resistant Depression (TRD).....II-19
Optimizing the Dosage.....II-19
Switching of Medications.....II-19
Combination therapy.....II-19
Augmentation Therapy.....II-19
Electroconvulsive Therapy.....II-19
1$100
   Facts and Figures on Depression.....II-20
Table 4: Global Antidepressants Market (2004): Percentage Breakdown of Prevalence Rate by Disorder Type – Depression, Anxiety, Obsessive Compulsive Disorder, Sleep Disorder, Panic Disorder, Phobias, and Others (include corresponding Graphs/Chart) .....II-20
Depression Hits the Elderly Hard.....II-20
1$300
   Men Vs Women – Who is More Depression Prone?.....II-211$100
   Depression and Smoking – Interlinked to One Another.....II-22
1$100
   What are Antidepressants? A Clear Understanding.....II-23
Global Antidepressants Market (2004): Select Brands and their Manufacturers.....II-23
Application Areas.....II-23
1$100
   Select Antidepressants and their Applications.....II-24
Types of Antidepressants.....II-24
1$100
   Tricyclic Antidepressants (TCAs).....II-25
Global Antidepressants Market: TCA Brands and Dosage Types - Starting Dosage and
  Normal Dosage.....II-25
1$100
   Global Antidepressants Market: TCAs and their Side Effects..... II-26
Monamine Oxidase Inhibitors (MAOIs).....II-26
Global Antidepressants Market: MAOI Brands and Dosage Types – Starting Dosage and
  Normal Dosage.....II-26
1$100
   Side Effects of Different MAOIs – Tranylcypromine; Isocarboxazid and
  Phenelzine.....II-27
Selective Serotonin Reuptake Inhibitors (SSRIs).....II-27
Global Antidepressants Market: SSRIs Brands and Related Dosage - Starting Dosage and
  Normal Dosage.....II-27
Pharmacology.....II-27
1$100
   FDA Approval.....II-28
Fluoxetine (Proxac).....II-28
Citalopram.....II-28
Fluvoxamine (Luvox).....II-28
1$100
   Paroxetine.....II-29
Sertraline (Zoloft).....II-29
Escitalopram.....II-29
Side Effects.....II-29
1$100
   Global Antidepressants Market: Different SSRI Drugs and their Side Effects.....II-30
Applications.....II-30
Global Antidepressants Market: SSRIs’ Off-Label Application Areas and
  Medication.....II-30
1$100
   New Generation Antidepressants.....II-31
Dopamine-Reuptake Blocking Compounds.....II-31
Bupropion.....II-31
Serotonin and Noradrenaline Reuptake Inhibitors.....II-31
Venlafaxine.....II-31
1$100
   5HT2 Receptor Antagonist Properties.....II-32
Nefazodone.....II-32
Trazodone.....II-32
Noradrenergic Antagonist.....II-32
Mirtazapine.....II-32
1$100
   Global Antidepressants Market: New Generation Drugs and Dosage Types - Starting
  Dosage and Normal Dosage.....II-33
Global Antidepressants Market: New Generation Antidepressants and their Side
  Effects.....II-33
1$100
   Global Antidepressants Market: Major Drugs by Class – SSRI, SNRI, MAOI, and
  NaSSA.....II-34
1$100
   Tracing the Line of History.....II-35
Antidepressants, a Mere Accidental Discovery.....II-35
Limited Choices and High Risk Rates.....II-35
Better Alternatives and Wider Choice – The New Mantra.....II-35
1$100
   Global Antidepressants Market: Launch of Drug Types – TCAs, MAOI, SSRI, and New
  Generation Variants by Original Version, Secondary Version, and Generic
    Version.....II-36
1$100
   Adverse Effects of Antidepressants and their Management.....II-37
Sedation.....II-37
Orthostatic Hypotension.....II-37
Insomnia.....II-37
1$100
   Anticholinergic Effects.....II-38
Weight Gain/Loss.....II-38
Sexual Dysfunction.....II-38
Side Effects Associated with Overdose.....II-38
1$100
   Choosing an Antidepressant.....II-39
Table 5: Global Antidepressants Market: Percentage Breakdown of Volume Drug Consumption by Disorder Type – Depression, Generalized Anxiety Disorder, Post Traumatic Stress Disorder, Panic Disorder and Others (include corresponding Graphs/Chart) .....II-39
1$300
   Switching Antidepressants.....II-40
Do Antidepressants Treat Depression Completely?.....II-40
1$100
   Are Antidepressants Addictive?.....II-41
Global Antidepressants Market: Withdrawal Symptoms by Drug Types - TCAs and
  SSRIs.....II-41
1$100
   Disorders and Antidepressants.....II-42
Bipolar Disorder.....II-42
Anxiety Disorder.....II-42
Panic Disorder.....II-42
1$100
   Antidepressants Used for Treatment of Panic Disorders, their
  Efficacy/Recommendations, and Side Effects.....II-43
A Note of Caution for Panic Patients Using Antidepressants.....II-43
Generalized Anxiety Disorder.....II-43
1$100
   SNRI.....II-44
SSRI.....II-44
TCAs.....II-44
Antidepressants Used for Treatment of Anxiety Disorders.....II-44
1$100
   Antidepressants: Causes For and Against.....II-45
Cause for Antidepressants:.....II-45
Antidepressants Effective in Curing Premenstrual Dysphoric Disorder.....II-45
1$100
   Antidepressants Offer Solution for Itching and Scratching.....II-46
Antidepressants Offer Hope for Autistic Children.....II-46
Antidepressants Minimize Hot Flushes and Night Sweats.....II-46
1$100
   Antidepressants’ Positive Effect on the Brain.....II-47
Longer Duration Antidepressants Treatment Prevents Relapse.....II-47
Antidepressants - A New Option for Sleep Apnea.....II-47
1$100
   SSRI Antidepressants May Prove Helpful in Cancer Treatment.....II-48
Antidepressants Relaxes Tremors.....II-48
Lesser Fear of Breast Cancer with Antidepressants.....II-48
Antidepressants for Reducing Chronic Back Pain.....II-48
Causes Against Antidepressants.....II-48
Greater Heart at Risk with Antidepressants.....II-48
1$100
   Antidepressants Dissipates Sexual Drive.....II-49
Hip Fractures Troubles Aged Patients.....II-49
1$100
   Antidepressants can be a Deadly Prescription for Kids.....II-50
Dental Problems with Antidepressants.....II-50
Facts/Myths About Antidepressants.....II-50
Are Pregnant Women at Risk from Antidepressants?.....II-50
1$100
   Is Breast Feeding Safe While on Antidepressants?.....II-51
Homeopathic Treatment Versus Antidepressants Treatment – Which is Better?.....II-51
1$100
   Recent Findings on Antidepressants.....II-52
1$100
   Monitoring Technology Foresees Antidepressants Effect .....II-53
Vagus Nerve Stimulation - Device for Treating Depression.....II-53
Global Antidepressants Market: FDA Approvals (2002-2004).....II-53
1$100
   GlaxoSmithKline Re-Introduces Paxil CR in US Market.....II-54
Ratiopharm Launches Ratio-Paroxetine in Canada.....II-54
Organon Introduces Zispin SolTab.....II-54
Apotex Releases Generic Version of Paxil.....II-54
GlaxoSmithKline Launches Paxil CR.....II-54
1$100
   Lundbeck Launches Lexapro.....II-55
1$100
   Pfizer Acquires Esperion.....II-56
Organon in Marketing Agreement with STADA.....II-56
Andrx Signs Marketing Agreement with Impax and Teva.....II-56
GlaxoSmithKline Collaborates with NeuroSearch.....II-56
Lundbeck in Marketing Accord with Janssen-Cilag.....II-56
1$100
   Lundbeck Allies with Abbott Laboratories.....II-57
Myriad Signs an Agreement with Abbott Laboratories.....II-57
Recordati Obtains Marketing Rights from H Lundbeck.....II-57
1$100
   AstraZeneca Plc (UK).....II-58
Bristol-Myers Squibb (USA).....II-58
Eli Lilly and Co. (USA).....II-58
1$100
   Forest Laboratories (USA).....II-59
GlaxoSmithKline Plc (UK).....II-59
1$100
   H. Lundbeck A/S (Denmark).....II-60
Merck & Co. (USA).....II-60
Novartis AG (Switzerland).....II-60
Organon International, Inc. (USA).....II-60
1$100
   Pfizer, Inc. (USA).....II-61
Solvay SA (Brussels).....II-61
Wyeth Pharmaceuticals (USA).....II-61
2$200
   Table 6: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region – USA, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .....II-631$300
   Table 7: World 10-Year Perspective for Antidepressants by Geographic Region – Percentage Breakdown of Dollar Sales for USA, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Latin America Markets for Years 2000, 2005 & 2010 (include corresponding Graphs/Chart) .....II-641$300
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
Market Overview.....III-1
Antidepressants Usage in the United States .....III-1
1$75
   US Antidepressants Market: Drug Usage.....III-2
Competitive Scenario.....III-2
Table 8:Leading Players in the US Antidepressants Market (2004 & 2005(E)): Percentage Breakdown of Value Sales for Forest Labs, GlaxoSmithKline, Pfizer, Wyeth, Eli Lilly and Others (include corresponding Graphs/Chart) .....III-2
1$150
   Table 9: Leading Players in the US SSRI/SNRI Market (2004 & 2005(E)): Percentage Breakdown of Value Sales for Forest Labs, Pfizer, Wyeth, GlaxoSmithKline, Eli Lilly and Others (include corresponding Graphs/Chart) .....III-3
Trends and Issues.....III-3
Are Americans Getting Too Depressed?.....III-3
1$150
   New Drugs Set to Conquer the Market.....III-4
Table 10: Leading SSRI/ SNRI Brands in the US Antidepressants Market (2000-2005(E)): Percentage Breakdown of Sales for Prozac, Paxil, Zoloft, Celexa, Lexapro, Effexor and Others (include corresponding Graphs/Chart) .....III-4
1$150
   Table 11: US Antidepressants Market (2000-2003): Number of SSRI/SNRI Prescriptions Dispensed in Millions (include corresponding Graphs/Chart) .....III-5

Table 12: US Antidepressants Market (2000): Advertising Expenditure in US$ Million on Select SSRIs - Celexa (Citalopram), Prozac (Fluoxetine), Effexor XR (Venlafaxine), Zoloft (Sertraline), Paxil (Paroxetine), and Luvox (Fluvoxamine) (include corresponding Graphs/Chart) .....III-5
Depression More Common Among Gays.....III-5
1$150
   FDA Inspects Suicidal Tendencies in Kids on Antidepressants.....III-6
FDA Imposes "black-box" Warning.....III-6
1$75
   Generic Drugs Pose Competition to Branded Drugs.....III-7
Table 13: Leading SSRI Brands in the US Antidepressants Market (2001): Sales in US$ Million for Zoloft, Paxil, Prozac & Sarafem, Celexa, and Luvox (include corresponding Graphs/Chart) .....III-7
Depression Drugs Being Used for Symptoms Other Than Depression.....III-7
1$150
   US Antidepressants Market: Drugs Approved for Different Indications.....III-8
Frequent Patent Expiries – A Cause of Concern for Manufacturers.....III-8
Patent Expiry of Select Antidepressant Brands in the United States .....III-8
1$75
   Product Launches/Developments.....III-91$75
   Strategic Corporate Developments.....III-10
Key Players..... III-10
Bristol-Myers Squibb.....III-10
1$75
   Eli Lilly and Co......III-11
Forest Laboratories.....III-11
Merck & Co......III-11
1$75
   Organon International, Inc......III-12
Pfizer, Inc......III-12
Wyeth Pharmaceuticals.....III-12
1$75
   B. Market Analytics.....III-13
Table 14: US Recent Past, Current & Future Analysis for Antidepressants by Product Segment – SSRI, New Generation, TCA and MAOI Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .....III-13
1$150
   Table 15: US 10-Year Perspective for Antidepressants by Product Segment – Percentage Breakdown of Dollar Sales for SSRI, New Generation, TCA and MAOI for Years 2000, 2005 & 2010 (include corresponding Graphs/Chart) .....III-14
1$150
   A. Market Analysis.....III-15
Current and Future Analysis.....III-15
Market Overview.....III-15
Increasing Use of Antidepressants among Canadian Women.....III-15
Antidepressants Market - A Recent Past Perspective.....III-15
1$75
   Table 16: Canadian Antidepressants Market (2001): Percentage Breakdown of Value Sales by Class – SSRI, TCAs, MOAI, and Others (include corresponding Graphs/Chart) .....III-16
Generic Serzone Recalled from Canadian Market in 2003.....III-16
Warning Against Antidepressants Use in Under- 18 Age Group.....III-16
1$150
   Product Launch.....III-17
B. Market Analytics.....III-17
Table 17: Canadian Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .....III-17
1$150
   A. Market Analysis.....III-18
Current and Future Analysis.....III-18
Recent Past Perspective.....III-18
1$75
   Table 18: CNS Market in Japan (2001): Sales in US$ Million by Drug Class – Antidepressants, Antiulcerants, Cholesterol Reducers, Broad Antibiotic, Antiarrhythmic, Antihypertensive, Narcotic painkiller, Oral Diabetes, Oral Antihistamine, and Antiseizure (include corresponding Graphs/Chart) .....III-19
Competitive Scenario.....III-19
1$150
   Table 19: Leading Brands in the Japanese Antidepressants Market (2001 & 2002): Percentage Breakdown of Value Sales for Paxil, Luvox, Depromel, Ludiomil, Toledomin, Toledomin- Jansen, Anafranil, Tetramide, and Others (include corresponding Graphs/Chart) .....III-20
A Historical Perspective.....III-20
1$150
   Antidepressants Market in Japan – Major Drug Launches the Period 1973-2000.....III-211$75
   B. Market Analytics.....III-22
Table 20: Japanese Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .....III-22
1$150
   A. Market Analysis.....III-23
Current and Future Analysis.....III-23
Market Overview.....III-23
1$75
   Table 21: Leading Players in the European Antidepressants Market (2004 & 2005(E)) – Percentage Breakdown of Value Sales for GlaxoSmithKline, Eli Lilly, Lundbeck, Pfizer, Wyeth and Others (include corresponding Graphs/Chart) .....III-24
Changes in European Patent Litigation.....III-24
Strategic Corporate Developments.....III-24
1$150
   B. Market Analytics.....III-25
Table 22: European Recent Past, Current & Future Analysis for Antidepressants by Geographic Region – France, Germany, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .....III-25
1$150
   Table 23: European 10-Year Perspective for Antidepressants by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, and Rest of Europe Markets for Years 2000, 2005 & 2010 (include corresponding Graphs/Chart) .....III-26
1$150
   Market Analysis.....III-27
Current and Future Analysis.....III-27
Table 24: French Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .....III-27
1$150
   Market Analysis.....III-28
Current and Future Analysis.....III-28
Table 25: German Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .....III-28
1$150
   A. Market Analysis.....III-29
Current and Future Analysis.....III-29
Market Overview.....III-29
A Recent Past Perspective.....III-29
UK Bans Antidepressant Use in Children (2003).....III-29
1$150
   Table 26: Antidepressants Market in the UK (1993-2000): Number of Associated Deaths in England and Wales by Drug Class – TCAs, MAOIs, SSRIs and Others (include corresponding Graphs/Chart) .....III-30
Prescriptions and Expenditure Statistics.....III-30
Regional Analysis – Scotland.....III-30
Antidepressants, a Happy Pill for Sad Scots.....III-30
1$150
   Key Players.....III-31
AstraZeneca.....III-31
GlaxoSmithKline.....III-31
1$75
   B. Market Analytics.....III-32
Table 27: UK Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .....III-32
1$150
   Market Analysis.....III-33
Current and Future Analysis.....III-33
Table 28: Italian Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .....III-33
1$150
   Market Analysis.....III-34
Current and Future Analysis.....III-34
Table 29: Spanish Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .....III-34
1$150
   A. Market Analysis.....III-35
Current and Future Analysis.....III-35
Focus on Select Regional Markets.....III-35
Denmark.....III-35
Danish People Display Greater Preference for Antidepressants.....III-35
Finland.....III-35
Antidepressants Consumption Increases Among Young Adults.....III-35
Key Players.....III-35
H. Lundbeck A/S (Denmark).....III-35
1$75
   Novartis AG (Switzerland).....III-36
Solvay SA (Brussels).....III-36
B. Market Analytics.....III-36
Table 30: Rest of Europe Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 III-34 (include corresponding Graphs/Chart) .....III-36
1$150
   A. Market Analysis.....III-37
Current and Future Analysis.....III-37
Australia.....III-37
A Recent Past Market Perspective.....III-37
Commonly Used Antidepressants in Australia (2001).....III-37
1$75
   Strategic Corporate Development.....III-38
B. Market Analytics.....III-38
Table 31: Asia-Pacific Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .....III-38
1$150
   A. Market Analysis.....III-39
Current and Future Analysis.....III-39
Chile.....III-39
High Usage of Antidepressants among Chileans.....III-39
Strategic Corporate Development.....III-39
1$75
   B. Market Analytics.....III-40
Table 32: Latin America Recent Past, Current & Future Analysis for Antidepressants: Annual Sales Figures in US$ Million for Years 2000 through 2010 (include corresponding Graphs/Chart) .....III-40
1$150
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com